NCT01235975View on ClinicalTrials.gov

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 29, 2011

Study Completion Date

August 3, 2011

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine GSK 134612

Intramuscular injection

BIOLOGICAL

MencevaxACWY TM

Subcutaneous injection

Trial Locations (1)

1107-2020

GSK Investigational Site, Beirut

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY